Results 111 to 120 of about 1,503 (160)
The impact of peritoneal dialysis on oxypurinol and urate elimination in people with gout
NephrologyAbstractGout affects 15%–30% of individuals with advanced kidney disease. Allopurinol which is rapidly and extensively metabolised to an active metabolite, oxypurinol, is the most commonly prescribed urate‐lowering therapy. Oxypurinol is almost entirely eliminated by the kidneys (>95%) and has an elimination half‐life of 18–30 h in those with normal
Suetonia Palmer +2 more
exaly +4 more sources
The pharmacokinetics of oxypurinol in people with gout [PDF]
British Journal of Clinical Pharmacology, 2012 WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT• Response to allopurinol in patients with gout is often suboptimal due to large variability in pharmacokinetics.• The sources of the variability in oxypurinol pharmacokinetics have not been systematically identified and quantified.• A therapeutic target 15–23 mg l−1for oxypurinol concentrations has recently been
Sophie Stocker +2 more
exaly +7 more sources
Allopurinol and oxypurinol are hydroxyl radical scavengers [PDF]
FEBS Letters, 1987 Allopurinol is a scavenger of the highly reactive hydroxyl radical (k 2 approx. 109 M−1s−1). One product of attack of hydroxyl radical upon allopurinol is oxypurinol, which is a major metabolite of allopurinol. Oxypurinol is a better hydroxyl radical scavenger than is allopurinol (k 2 approx.
Barry Halliwell +2 more
exaly +3 more sources
Effect of Oxypurinol on Renal Reperfusion Injury in the Rat
Renal Failure, 1993 Oxygen-based free radicals produced by the enzyme xanthine oxidase may be involved in postischemic reperfusion injury. To determine whether oxypurinol, a xanthine oxidase inhibitor and the major metabolite of allopurinol, attenuates renal ischemic reperfusion injury, and, if so, to determine its most effective dose, oxypurinol 2.5, 5, 10 or 20 mg/kg BW
William F Finn, W F Finn
exaly +3 more sources
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Oxypurinol attenuates ischemia-induced hippocampal damage in the gerbil
Brain Research Bulletin, 1989Oxypurinol, an inhibitor of the enzyme xanthine oxidase, reduced ischemic hippocampal damage and the associated hypermotility in Mongolian gerbils. Cerebral ischemia was induced in unanesthetized gerbils by a bilateral 5-min occlusion of the carotid arteries.
J W Phillis, J W Phillis
exaly +3 more sources
An allopurinol adherence tool using plasma oxypurinol concentrations
British Journal of Clinical Pharmacology, 2022AbstractAimsThis study aimed to develop and evaluate an allopurinol adherence tool based on steady‐state oxypurinol plasma concentrations, allopurinol's active metabolite.MethodsPlasma oxypurinol concentrations were simulated stochastically from an oxypurinol pharmacokinetic model for allopurinol doses of 100‐800 mg daily, accounting for differences in
Natalia Smith‐Diaz +6 more
openaire +2 more sources
The population pharmacokinetics of allopurinol and oxypurinol in patients with gout
European Journal of Clinical Pharmacology, 2013The aims of this study were to develop a population pharmacokinetic model for allopurinol and oxypurinol and to explore the influence of patient characteristics on allopurinol and oxypurinol pharmacokinetics.Data from 92 patients with gout and 12 healthy volunteers were available for analysis.
Daniel F B Wright +2 more
exaly +3 more sources
Clinical Pharmacokinetics and Pharmacodynamics of Allopurinol and Oxypurinol
Clinical Pharmacokinetics, 2007Allopurinol is the drug most widely used to lower the blood concentrations of urate and, therefore, to decrease the number of repeated attacks of gout. Allopurinol is rapidly and extensively metabolised to oxypurinol (oxipurinol), and the hypouricaemic efficacy of allopurinol is due very largely to this metabolite.
Richard O, Day +5 more
openaire +2 more sources
Oxypurinol Protects Normothermic Ischemic Hearts
Journal of Cardiac Surgery, 1990Rabbit hearts were mounted on a Langendorff apparatus and after measurement of baseline hemodynamic function exposed to 30 minutes normothermic arrest. Hearts were reperfused at 37 degrees C with buffer solution containing oxypurinol in different concentration: group II (0.01 mM), group III (0.1 mM), group IV (1 mM). Group I did not receive active drug
J, Bergsland +4 more
openaire +2 more sources
Allopurinol and oxypurinol in human breast milk
The Clinical Investigator, 1993To pregnant or breast feeding women drugs should be given with caution. We report the case of a 5-week-old breast-fed infant whose mother was taking 300mg allopurinol/day for 4 weeks. Allopurinol and oxypurinol were detected by HPLC in maternal plasma and breast milk with a method first described here.
I, Kamilli, U, Gresser
openaire +2 more sources